Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Plöger, Gerlinde FAbrahamsson, Bertil
Cristofoletti, Rodrigo
Groot, D I R K W
Langguth, Peter
Mehta, Mehul U
Parr, Alan
Polli, James E
Shah, Vinod P
Tajiri, Tomokazu
Dressman, Jennifer B
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride.Published in
Tijdschrift Tijdschrift J Pharm Sci 2018; 107(7):1761-72Publiekssamenvatting
Literature data relevant to the decision to waive in vivo bioequivalence testing for the approval of generic immediate release solid oral dosage forms of proguanil hydrochloride are reviewed. To clarify the Biopharmaceutics Classification System (BCS) classification, experimental solubility and dissolution studies were also carried out. The antimalarial proguanil hydrochloride, effective via the parent compound proguanil and the metabolite cycloguanil, is not considered to be a narrow therapeutic index drug. Proguanil hydrochloride salt was shown to be highly soluble according to the FDA, WHO and EMA guidelines, but data for permeability are inconclusive. Therefore, proguanil hydrochloride is conservatively classified as a BCS Class 3 substance. In view of this information and the assessment of risks associated with a false positive decision, a BCS-based biowaiver approval procedure can be recommended for orally administered solid IR products containing proguanil hydrochloride, provided well-known excipients are used in usual amounts and provided the in vitro dissolution of the test and reference products is very rapid (85% or more are dissolved in 15 minutes at pH 1.2, 4.5 and 6.8) and is performed according to the current requirements for BCS-based biowaivers.PMID
29571740ae974a485f413a2113503eed53cd6c53
10.1016/j.xphs.2018.03.009
Scopus Count
Collections
Related articles
- Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride.
- Authors: Metry M, Shu Y, Abrahamsson B, Cristofoletti R, Dressman JB, Groot DW, Parr A, Langguth P, Shah VP, Tajiri T, Mehta MU, Polli JE
- Issue date: 2021 Apr
- Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride.
- Authors: Strauch S, Jantratid E, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM
- Issue date: 2011 Jan
- Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride.
- Authors: Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, Shah VP, Dressman JB
- Issue date: 2012 Dec
- Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate.
- Authors: Thambavita D, Galappatthy P, Mannapperuma U, Jayakody L, Cristofoletti R, Abrahamsson B, Groot DW, Langguth P, Mehta M, Parr A, Polli JE, Shah VP, Dressman J
- Issue date: 2017 Oct
- Biowaiver monographs for immediate-release solid oral dosage forms: primaquine phosphate.
- Authors: Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, Shah VP, Dressman JB
- Issue date: 2012 Mar